5 results match your criteria: "ProMedica Neurosciences Center[Affiliation]"
Sex and Gender Differences in Alzheimer's Disease: Genetic, Hormonal, and Inflammation Impacts.
Int J Mol Sci
August 2024
Department of Neurology, Mitchell Center for Neurodegenerative Diseases, School of Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA.
Two-thirds of Americans with Alzheimer's disease are women, indicating a profound variance between the sexes. Variances exist between the sexes in the age and intensity of the presentation, cognitive deficits, neuroinflammatory factors, structural and functional brain changes, as well as psychosocial and cultural circumstances. Herein, we summarize the existing evidence for sexual dimorphism and present the available evidence for these distinctions.
View Article and Find Full Text PDFNeurocritical Care of the Pregnant Patient.
Curr Treat Options Neurol
June 2021
Department of Neurology, Washington University, St. Louis, MO USA.
Purpose Of Review: To summarize recent changes in management and emerging therapies for pregnant neurocritical care patients.
Recent Findings: Diagnostic and treatment options for managing neurologic emergencies in pregnant patients have expanded with both greater understanding of the effects of imaging modalities and medications on pregnancy and application of standard treatments for non-pregnant patients to pregnant populations. Specifically, this includes cerebrovascular diseases (pregnancy-associated ischemic stroke, pregnancy-associated intracerebral hemorrhage, cerebral venous sinus thrombosis), post-maternal cardiac arrest care, seizures and status epilepticus, myasthenia gravis, and fetal somatic support in maternal death by neurologic criteria.
Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series.
Front Neurol
June 2021
ProMedica Neurosciences Center, Toledo, OH, United States.
Article Synopsis
- Neurointerventional procedures for acute ischemic stroke often need quick antiplatelet therapy, and intravenous cangrelor, a fast-acting drug, was studied for its safety and effectiveness during treatment.
- A study involved 12 patients who received cangrelor during acute treatments, where outcomes like in-stent thrombosis and functional recovery at 90 days were assessed; no significant complications were reported.
- Results indicated that low-dose intravenous cangrelor showed similar safety and efficacy compared to oral antiplatelets in this small sample, suggesting a need for larger studies to further investigate its use in neurointerventional procedures.
Neurological Predictors of Clinical Outcomes in Hospitalized Patients With COVID-19.
Front Neurol
October 2020
ProMedica Neurosciences Center, Toledo, OH, United States.
Multiple risk factors of mortality have been identified in patients with COVID-19. Here, we sought to determine the effect of a history of neurological disorder and development of neurological manifestations on mortality in hospitalized patients with COVID-19. From March 20 to May 20, 2020, hospitalized patients with laboratory confirmed or highly suspected COVID-19 were identified at four hospitals in Ohio.
View Article and Find Full Text PDFInterventional Stroke Care in the Era of COVID-19.
Front Neurol
May 2020
Department of Neurology, University of Toledo, Toledo, OH, United States.
The current coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 has led to immense strain on healthcare systems and workers. Patients with severe symptoms of COVID-19 may also present with acute neurological emergencies such as ischemic stroke. Ischemic stroke in these patients may result from COVID-19 related complications or decompensation of previously asymptomatic cerebrovascular disorders, or concurrent ischemic stroke from common stroke risk factors in a patient with COVID-19.
View Article and Find Full Text PDF